Karen Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4893379/publications.pdf

Version: 2024-02-01

99 papers	9,966 citations	101543 36 h-index	37204 96 g-index
100 all docs	100 docs citations	100 times ranked	19983 citing authors

#	Article	IF	Citations
1	Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a â€œdietary-achievableâ€•or â€œpharmacologicalâ€•dose: what are the implications for anticancer activity?. American Journal of Clinical Nutrition, 2021, 113, 1115-1125.	4.7	8
2	A Systematic Review Assessing Clinical Utility of Curcumin with a Focus on Cancer Prevention. Molecular Nutrition and Food Research, 2021, 65, e2000977.	3.3	15
3	A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps. International Journal of Molecular Sciences, 2021, 22, 11024.	4.1	16
4	WITHDRAWALâ€”Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. Tumori, 2020, 106, NP2-NP4.	1.1	1
5	New Paradigms to Assess Consequences of Long-Term, Low-Dose Curcumin Exposure in Lung Cancer Cells. Molecules, 2020, 25, 366.	3.8	7
6	Resveratrol for Cancer Prevention: Current Gaps and Opportunities. , 2020, , 19-47.		2
7	Therapeutic cancer prevention: achievements and ongoing challenges â€“ a focus on breast and colorectal cancer. Molecular Oncology, 2019, 13, 579-590.	4.6	27
8	Cancer Prevention Europe. Molecular Oncology, 2019, 13, 528-534.	4.6	70
9	Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. Journal of Nutrition, 2019, 149, 1133-1139.	2.9	125
10	Effects of a Grapevine Shoot Extract Containing Resveratrol and Resveratrol Oligomers on Intestinal Adenoma Development in Mice: In Vitro and In Vivo Studies. Molecular Nutrition and Food Research, 2018, 62, 1700450.	3.3	10
11	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death and Disease, 2018, 9, 894.	6.3	34
12	Detection of Plasma Curcuminoids from Dietary Intake of Turmericâ€Containing Food in Human Volunteers. Molecular Nutrition and Food Research, 2018, 62, e1800267.	3.3	21
13	Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE). Journal of Cancer Policy, 2018, 17, 15-23.	1.4	32
14	An HPLCâ€UV method for the simultaneous quantification of curcumin and its metabolites in plasma and lung tissue: Potential for preclinical applications. Biomedical Chromatography, 2018, 32, e4280.	1.7	9
15	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. Scientific Reports, 2018, 8, 12096.	3.3	55
16	Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis. European Journal of Cancer Prevention, 2017, 26, 277-284.	1.3	0
17	Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPsâ€™ attitudes. British Journal of General Practice, 2017, 67, e414-e427.	1.4	33
18	General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. Familial Cancer, 2017, 16, 509-516.	1.9	13

#	Article	IF	Citations
19	Targeting cancer stemâ€like cells using dietaryâ€derived agents â€“ Where are we now?. Molecular Nutrition and Food Research, 2016, 60, 1295-1309.	3.3	19
20	Response to comment on â€œCancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and miceâ€. Science Translational Medicine, 2016, 8, 350lr2.	12.4	0
21	The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?. International Journal of Cancer, 2016, 138, 30-44.	5.1	31
22	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
23	InÂvivo relevant mixed urolithins and ellagic acid inhibit phenotypic and molecular colon cancer stem cell features: A new potentiality for ellagitannin metabolites against cancer. Food and Chemical Toxicology, 2016, 92, 8-16.	3.6	58
24	Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Annals of the New York Academy of Sciences, 2015, 1348, 124-133.	3.8	91
25	New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers. Ecancermedicalscience, 2015, 9, 601.	1.1	9
26	Do Not Throw Out the Resveratrol With the Bath Water. JAMA Internal Medicine, 2015, 175, 140.	5.1	3
27	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Science Translational Medicine, 2015, 7, 298ra117.	12.4	137
28	Inhibition of prostate cancer cell growth by 3â€²,4â€²,5â€²-trimethoxyflavonol (TMFol). Cancer Chemotherapy and Pharmacology, 2015, 76, 179-185.	2.3	9
29	Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials, 2015, 16, 110.	1.6	57
30	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Letters, 2015, 364, 135-141.	7.2	147
31	Characterization and Propagation of Tumor Initiating Cells Derived from Colorectal Liver Metastases: Trials, Tribulations and a Cautionary Note. PLoS ONE, 2015, 10, e0117776.	2.5	6
32	Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy, 2014, 10, 524-525.	9.1	42
33	Anthocyans as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C. Mutagenesis, 2014, 29, 227-235.	2.6	13
34	Cancer chemoprevention. European Journal of Cancer Prevention, 2014, 23, 594-601.	1.3	2
35	Translating Curcumin to the Clinic for Lung Cancer Prevention: Evaluation of the Preclinical Evidence for Its Utility in Primary, Secondary, and Tertiary Prevention Strategies. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 483-494.	2.5	22
36	Resveratrol in the management of human cancer: how strong is the clinical evidence?. Annals of the New York Academy of Sciences, 2013, 1290, 12-20.	3.8	54

#	Article	IF	Citations
37	The role of cancer stem cells in the antiâ€carcinogenicity of curcumin. Molecular Nutrition and Food Research, 2013, 57, 1630-1637.	3.3	33
38	Novel analogues of resveratrol: metabolism and inhibition of colon cancer cell proliferation. Tetrahedron, 2013, 69, 6203-6212.	1.9	3
39	Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence. Science Translational Medicine, 2013, 5, 205ra133.	12.4	163
40	Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administrationâ€"A Clinical Pilot Study Including Assessment of Patient Acceptability. Cancer Prevention Research, 2013, 6, 119-128.	1.5	89
41	Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents. European Journal of Medicinal Chemistry, 2012, 54, 952-958.	5.5	38
42	Methods for the Detection of DNA Adducts. Methods in Molecular Biology, 2012, 817, 207-230.	0.9	17
43	Dietary intake of rosmarinic acid by Apc^{Min} mice, a model of colorectal carcinogenesis: levels of parent agent in the target tissue and effect on adenoma development. Molecular Nutrition and Food Research, 2012, 56, 775-783.	3.3	13
44	Tissue distribution and metabolism of the putative cancer chemopreventive agent 3â€²,4â€²,5â€²â€trimethoxyflavonol (TMFol) in mice. Biomedical Chromatography, 2012, 26, 1559-1566.	1.7	5
45	Resveratrol in human cancer chemoprevention â€“ Choosing the â€˜rightâ€™ dose. Molecular Nutrition and Food Research, 2012, 56, 7-13.	3.3	102
46	Curcumin: The potential for efficacy in gastrointestinal diseases. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 519-534.	2.4	73
47	Clinical trials of resveratrol. Annals of the New York Academy of Sciences, 2011, 1215, 161-169.	3.8	400
48	Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3â€²,4â€²,5â€²,5,7-pentamethoxyflavone and tricin (4â€²,5,7-trihydroxy-3â€²,5â€²-dimethoxyflavone). Cancer Chemotherapy and Pharmacology, 2011, 67, 255-263.	2.3	17
49	Curcumin ameliorates oxaliplatinâ€induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. International Journal of Cancer, 2011, 129, 476-486.	5.1	77
50	Determination of anthocyanins in the urine of patients with colorectal liver metastases after administration of bilberry extract. Biomedical Chromatography, 2011, 25, 660-663.	1.7	25
51	Longitudinal Changes in Patient Distress following Interactive Decision Aid Use amongBRCA1/2Carriers. Medical Decision Making, 2011, 31, 412-421.	2.4	51
52	N-Methylpurine DNA Glycosylase Plays a Pivotal Role in the Threshold Response of Ethyl Methanesulfonateâ€“Induced Chromosome Damage. Toxicological Sciences, 2011, 119, 346-358.	3.1	39
53	What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. PLoS ONE, 2011, 6, e19881.	2.5	375
54	BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment, 2010, 124, 755-764.	2.5	25

#	Article	IF	Citations
55	Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. Cancer Research, 2010, 70, 9003-9011.	0.9	542
56	Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3â€²,4â€²,5â€²-Trimethoxyflavonol, a Quercetin Analogue. Cancer Prevention Research, 2010, 3, 929-939.	1.5	22
57	Anthocyanin-rich red grape extract impedes adenoma development in the ApcMin mouse: Pharmacodynamic changes and anthocyanin levels in the murine biophase. European Journal of Cancer, 2010, 46, 811-817.	2.8	25
58	Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. Cancer Research, 2010, 70, 7392-7399.	0.9	511
59	Abstract A104: 3â€™, 4â€™, 5â€™-Trimethoxyflavonol (TMFol), a novel putative prostate cancer chemopreventive agent: In vitro and in vivo preclinical activity. , 2010, , .		3
60	Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials. Cancer Prevention Research, 2009, 2, 525-530.	1.5	66
61	Flavones as Colorectal Cancer Chemopreventive Agentsâ€"Phenol-O-Methylation Enhances Efficacy. Cancer Prevention Research, 2009, 2, 743-750.	1.5	52
62	Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis, 2009, 24, 391-404.	2.6	33
63	Dose-Response Relationships for N7-(2-Hydroxyethyl)Guanine Induced by Low-Dose [14C]Ethylene Oxide: Evidence for a Novel Mechanism of Endogenous Adduct Formation. Cancer Research, 2009, 69, 3052-3059.	0.9	34
64	Pilot Study of Oral Anthocyanins for Colorectal Cancer Chemoprevention. Cancer Prevention Research, 2009, 2, 625-633.	1.5	109
65	Determination of 3â€²,4â€²,5â€²,5,7â€pentamethoxyflavone in the plasma and intestinal mucosa of mice by HPLC with UV detection. Biomedical Chromatography, 2009, 23, 335-339.	1.7	3
66	Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice. Cancer Chemotherapy and Pharmacology, 2009, 64, 1261-1268.	2.3	89
67	Synthesis of the flavonoid 3â€²,4â€²,5â€²-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 939-942.	2.3	5
68	APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. European Journal of Cancer, 2009, 45, 2731-2735.	2.8	7
69	Mutagenicity of DNA adducts derived from ethylene oxide exposure in the pSP189 shuttle vector replicated in human Ad293 cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 678, 129-137.	1.7	26
70	Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: Impact on measures of decision making and satisfaction.. Health Psychology, 2009, 28, 11-19.	1.6	94
71	Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.. Health Psychology, 2009, 28, 569-578.	1.6	41
72	Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemotherapy and Pharmacology, 2008, 62, 369-372.	2.3	11

#	Article	IF	Citations
73	Simultaneous detection of five different 2â€hydroxyethylâ€DNA adducts formed by ethylene oxide exposure, using a highâ€performance liquid chromatography/electrospray ionisation tandem mass spectrometry assay. Rapid Communications in Mass Spectrometry, 2008, 22, 19-28.	1.5	25
74	Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels. European Journal of Cancer, 2008, 44, 898-906.	2.8	38
75	Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots. Nucleic Acids Research, 2008, 36, 5933-5945.	14.5	10
76	Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose. Cancer Research, 2007, 67, 6995-7002.	0.9	29
77	Determination of Endogenous and Exogenously Derived N7-(2-Hydroxyethyl)guanine Adducts in Ethylene Oxide-Treated Rats. Chemical Research in Toxicology, 2007, 20, 290-299.	3.3	35
78	A novel 14C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy-guanosine adducts. Rapid Communications in Mass Spectrometry, 2006, 20, 883-891.	1.5	15
79	Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spectrometry Reviews, 2006, 25, 127-145.	5.4	62
80	Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS). Nucleic Acids Research, 2006, 34, e150-e150.	14.5	4
81	Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods. Mutagenesis, 2005, 20, 115-124.	2.6	15
82	Mutation Spectra Induced by Î±-Acetoxytamoxifenâ€'DNA Adducts in Human DNA Repair Proficient and Deficient (Xeroderma Pigmentosum Complementation Group A) Cells. Biochemistry, 2005, 44, 8198-8205.	2.5	15
83	Accelerator Mass Spectrometry for Biomedical Research. Methods in Enzymology, 2005, 402, 423-443.	1.0	56
84	Techniques: The application of accelerator mass spectrometry to pharmacology and toxicology. Trends in Pharmacological Sciences, 2004, 25, 442-447.	8.7	27
85	Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers. Journal of Genetic Counseling, 2003, 12, 109-129.	1.6	29
86	Structural characterization of carcinogen-modified oligodeoxynucleotide adducts using matrix-assisted laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry, 2003, 38, 68-79.	1.6	16
87	Correspondence regarding M. Sharma et al., â€œAntioxidant inhibits tamoxifenâ€“DNA adducts in endometrial explant cultureâ€. Biochemical and Biophysical Research Communications, 2003, 310, 1039.	2.1	4
88	Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Research, 2003, 63, 8461-5.	0.9	53
89	Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opinion on Drug Safety, 2002, 1, 253-267.	2.4	62
90	Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 2002, 23, 1897-1902.	2.8	81

#	Article	IF	Citations
91	DNA Adducts Formed from 4-Hydroxytamoxifen Are More Mutagenic than Those Formed by Î±-Acetoxytamoxifen in a Shuttle Vector Target Gene Replicated in Human Ad293 Cells. Biochemistry, 2002, 41, 8899-8906.	2.5	25
92	Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in Oncology, 2002, 29, 36-40.	2.2	80
93	Synthesis and spectroscopic characterization of site-specific 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine oligodeoxyribonucleotide adducts. Nucleic Acids Research, 2001, 29, 1951-1959.	14.5	18
94	Short-term dosing of Î±-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats. Carcinogenesis, 2001, 22, 553-557.	2.8	12
95	Chemoprevention of Breast Cancer by Tamoxifen: Risks and Opportunities. Critical Reviews in Toxicology, 2000, 30, 571-594.	3.9	72
96	Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis, 1999, 20, 2011-2016.	2.8	38
97	Site-Specific Tamoxifenâ^'DNA Adduct Formation:Â Lack of Correlation with Mutational Ability inEscherichiacoliâ€,â€¡. Biochemistry, 1999, 38, 10989-10996.	2.5	12
98	Determination of DNA Damage in F344 Rats Induced by Geometric Isomers of Tamoxifen and Analogues. Chemical Research in Toxicology, 1998, 11, 527-534.	3.3	22
99	A family with three germline mutations in BRCAl and BRCA2. Clinical Genetics, 1998, 54, 215-218.	2.0	13